相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Drug-Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2014)
Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study
Kaj Stenlof et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Diagnosis and Classification of Diabetes Mellitus
DIABETES CARE (2014)
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
T. Forst et al.
DIABETES OBESITY & METABOLISM (2014)
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes
David Polidori et al.
DIABETOLOGIA (2014)
Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Greg L. Plosker
DRUGS (2014)
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Canagliflozin: Effects in Overweight and Obese Subjects Without Diabetes Mellitus
Harold E. Bays et al.
OBESITY (2014)
Urinary Tract Infection in Randomized Phase III Studies of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
Lindsay E. Nicolle et al.
POSTGRADUATE MEDICINE (2014)
Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
Alan Sinclair et al.
BMC ENDOCRINE DISORDERS (2014)
Metabolism and Excretion of Canagliflozin in Mice, Rats, Dogs, and Humans
Rao N. V. S. Mamidi et al.
DRUG METABOLISM AND DISPOSITION (2014)
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial
Bruce Neal et al.
AMERICAN HEART JOURNAL (2013)
Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion Results of a randomized, placebo-controlled study
David Polidori et al.
DIABETES CARE (2013)
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A 52-week randomized trial
Guntram Schernthaner et al.
DIABETES CARE (2013)
Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study
N. Inagaki et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
J-F Yale et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
K. Stenlof et al.
DIABETES OBESITY & METABOLISM (2013)
Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?
M. Burgmaier et al.
DIABETIC MEDICINE (2013)
miRNA-30a-5p-mediated silencing of Beta2/NeuroD expression is an important initial event of glucotoxicity-induced beta cell dysfunction in rodent models
J. -W. Kim et al.
DIABETOLOGIA (2013)
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
F. J. Lavalle-Gonzalez et al.
DIABETOLOGIA (2013)
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
J. P. H. Wilding et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2013)
Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus
Damayanthi Devineni et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
Impact of Sodium Glucose Cotransporter 2 Inhibitors on Weight in Patients With Type 2 Diabetes Mellitus
Anthony H. Barnett
POSTGRADUATE MEDICINE (2013)
Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor
Paul Nyirjesy et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter Inhibitor, as Add-On to Meiformin in Subjects With Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Dapagliflozin A Review of its Use in Type 2 Diabetes Mellitus
Greg L. Plosker
DRUGS (2012)
Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats
James J. Devenny et al.
OBESITY (2012)
Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models
Yin Liang et al.
PLOS ONE (2012)
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
S. Sha et al.
DIABETES OBESITY & METABOLISM (2011)
Management of type 2 diabetes: new and future developments in treatment
Abd A. Tahrani et al.
LANCET (2011)
Sodium-Glucose Co-Transport Inhibitors Progress and Therapeutic Potential in Type 2 Diabetes Mellitus
Joshua J. Neumiller et al.
DRUGS (2010)
Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Sunil Nair et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Discovery of Canagliflozin, a Novel C-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Sumihiro Nomura et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk
A. L. PETERS
CLEVELAND CLINIC JOURNAL OF MEDICINE (2009)
Towards better understanding of the contributions of overwork and glucotoxicity to the β-cell inadequacy of type 2 diabetes
G. C. Weir et al.
DIABETES OBESITY & METABOLISM (2009)
Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications
George L. Bakris et al.
KIDNEY INTERNATIONAL (2009)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)